As­traZeneca dis­putes IRA’s or­phan drug pro­vi­sions in lat­est le­gal chal­lenge to the law

As­traZeneca is the lat­est phar­ma com­pa­ny to chal­lenge the In­fla­tion Re­duc­tion Act in court, this time ze­ro­ing in on the law’s pro­vi­sions around or­phan drugs.

The com­pa­ny filed a com­plaint Fri­day in US Dis­trict Court for the Dis­trict of Delaware, ar­gu­ing that the drug price ne­go­ti­a­tion pro­vi­sions in the IRA “run head­long” in­to the Or­phan Drug Act, which was passed in 1983 and is in­tend­ed to en­cour­age com­pa­nies to in­vest in treat­ments for rare dis­eases.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER